CSE’s Barrington Miller was recently joined by Christopher Moreau, CEO of Algernon Pharmaceuticals Inc. (CSE:AGN), to discuss his company’s work to develop NP-120 (Ifenprodil) as a new therapeutic in the fight against COVID-19.
In this discussion, Chris outlines how his company focuses on drug re-purposing, a term that is widely understood through the example provided by Viagra (1:04), the important distinction between therapeutic treatments and anti-virals and vaccines (12:14), and why the “grandaddy” of all market approvals is from the USFDA (18:25).
Listen until the end to hear how the company’s name is actually inspired by the title of a science fiction novel, and how the company has a history of investigating compounds developed by the Soviet Union!
(Subsequent to this chat, Algernon announced Health Canada approval to move forward with its PH2b/3 trial here with Ifenprodil as a potential treatment for COVID-19.)
Related Link
algernonpharmaceuticals.com
CSE’s Barrington Miller is rejoined by Alan Brochstein, founder of 420 Investor and contributor to New Cannabis Ventures, to discuss the recent issues surrounding the cannabis industry, with a specific focus on what’s happening in the United States and in the stock market. In this wide-ranging discussion, Alan shares what he thinks are the two…
CSE’s Barrington Miller recently caught-up with NexTech AR Solutions Corp. (CSE:NTAR) CEO Evan Gappelberg to discuss his company’s current state of operations during the Coronavirus outbreak in NYC. During this discussion, Evan provides commentary on the (positive) impact that the pandemic is having on his business (1:19), how their AR (augmented reality) technology fits within…
CSE’s James Black recently hosted Frank Holmes, CEO and CIO at U.S. Global Investors for his second visit to the #HashtagFinance podcast. In this discussion Frank shares his many investment observations including the global themes that are contributing to gold price speculation (1:50), why he thinks buying Bitcoin is now analogous to collecting art (7:07),…
